We found that the levels of combination signatures CM-2 (HYAL-1 + N-Cadh) and CM-6 (HYAL-1 + N-Cadh + HAS-2 + SNAI1 + Slug + MMP-9) were elevated 5–8-fold in tumor specimens from patients who had or developed metastasis during follow-up compared to those who did not (p < 0.0001; Figure 2B,C). The gene discussed is HAS2; the disease is neoplasm.